Paradigm Biopharmaceuticals (PBIGF) AI Stock Analysis

Paradigm Biopharmaceuticals

(Other OTC:PBIGF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthThe reported revenue growth indicates that the company has expanded its top line despite its small and volatile revenue base. If this growth can be sustained, it could improve operating scale, support broader commercial adoption, and provide a foundation for future margin improvement.

Negative Factors

Persistent UnprofitabilityPersistent losses and recurring negative gross profit show that the business has not established a stable, profitable operating model. Losses that remain large relative to revenue can consume capital, limit reinvestment capacity, and make future profitability dependent on significant improvement in scale or cost structure.

Paradigm Biopharmaceuticals (PBIGF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $7.45M
Dividend Yield: ―
Average Volume (3M): 110.54K
Price to Earnings (P/E): -1.6
Beta (1Y): -0.16
Revenue Growth: 64.49%
EPS Growth: -225.94%
Country: US
Employees: 12
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Paradigm Biopharmaceuticals Business Overview & Revenue Model

Company Description

Based in Melbourne, Australia, Paradigm Biopharmaceuticals Limited specializes in the repurposing of existing drugs, developing therapeutic solutions for human health. A central offering is an injectable formulation of pentosan polysulfate sodium, cu...

Paradigm Biopharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

PBIGF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:RCE	46Neutral	AUD 110.10M	-6.66	84.67%	―	―	42.51%
AU:ACW	44Neutral	AUD 162.72M	-8.54	-103.42%	―	―	5.88%
AU:DXB	44Neutral	AUD 126.08M	-4.12	362.74%	―	-22.13%	-108.82%
AU:BOT	41Neutral	AUD 27.63M	-0.28	-118.74%	―	499.47%	31.20%
AU:ATX	30Underperform	AUD 43.12M	-4.91	-18.71%	―	―	21.23%

* Healthcare Sector Average

Performance Comparison

PBIGF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
PBIGF	Paradigm Biopharmaceuticals Ltd.	0.01	-0.26	-95.93%
AU:ATX	Amplia Therapeutics Ltd.	0.08	-0.04	-30.00%
AU:ACW	Actinogen Medical Limited	0.04	0.00	7.89%
AU:DXB	Dimerix Limited	0.21	-0.25	-54.35%
AU:BOT	Botanix Pharmaceuticals Limited	0.01	-0.12	-92.00%
AU:RCE	Recce Pharmaceuticals Ltd.	0.35	-0.06	-14.46%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Paradigm Biopharmaceuticals AI Stock Analysis